Código QR (código de barras bidimensional)

Durvalumab Combined With Pemetrexed-Based Chemotherapy in Trial-Ineligible Patients With Mesothelioma: A Brief Report

Introduction: Chemoimmunotherapy is associated with promising activity in mesothelioma in phase II to III trials. Studies exploring this approach in patients ineligible for clinical trials are lacking. We assembled a cohort of patients receiving pemetrexed-based chemotherapy with durvalumab outside...

ver descrição completa

Na minha lista:
Principais autores: Ibiayi Dagogo-Jack, MD, Aubrey Lasko, PharmD, Elizabeth A. Krueger, NP, Kitman Tsang, NP, Revati Rao, MD, Grace Hambelton, BA, Subba R. Digumarthy, MD
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2025-05-01
coleção:JTO Clinical and Research Reports
Assuntos:
Mesothelioma
Chemoimmunotherapy
Immunotherapy
Durvalumab
Acesso em linha:http://www.sciencedirect.com/science/article/pii/S2666364324001450
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados